澳股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

IMMUTEP LTD

0.365

-0.015-3.95%

成交量：288.50萬

成交額：106.42萬

市值：5.38億

市盈率：-8.65

高：0.380

開：0.380

低：0.360

收：0.380

52周最高：0.470

52周最低：0.222

股本：14.74億

流通股本：12.28億

量比：0.80

換手率：0.23%

股息：- -

股息率：- -

每股收益(TTM):-0.042

每股收益(LYR):-0.042

淨資產收益率：-36.88%

總資產收益率：-22.66%

市淨率：3.74

市盈率(LYR):-8.65

資料載入中...

總覽公司新聞資訊公告

概念

醫藥生物股-0.85%

資金流向

資金流入：

資金流出：

新聞資訊

IMMUTEP LTD發布關於Imp761的積極進展：首個針對自身免疫疾病的Lag-3激動劑抗體的I期研究結果

Immutep與Dr. Reddy's達成戰略合作推廣創新腫瘤藥物Eftilagimod Alfa

IMMUTEP LTD - DR. Reddy's 獲得所有北美、歐洲、日本及大中華區外國家的Eftilagimod Alfa獨家權利

IMMUTEP與DR. Reddy’s達成戰略合作，共同推廣創新腫瘤藥物Eftilagimod Alfa

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IMM.AU"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.365,"timestamp":1770354720000,"preClose":0.38,"halted":0,"volume":2885030,"delay":0,"changeRate":-0.03947368421052635,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.042199,"marketStatus":"休市中","change":-0.015,"latestTime":"02-06 16:12:00 AEDT","open":0.38,"high":0.38,"low":0.36,"amount":1064161,"amplitude":0.052632,"askPrice":0.37,"askSize":38442,"bidPrice":0.365,"bidSize":1654,"shortable":3,"etf":0,"ttmEps":-0.042199,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":0,"beginTime":1770591600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.38,"openAndCloseTimeList":[[1770332400000,1770354000000]],"volumeRatio":0.7999266016410244,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-22.66%","roe":"-36.88%","lyrEps":-0.042199,"volumeRatio":0.7999266016410244,"shares":1473721306,"dividePrice":0,"high":0.38,"amplitude":0.052632,"preClose":0.38,"low":0.36,"week52Low":0.222,"pbRate":"3.74","psRate":"106.65","week52High":0.47,"institutionHeld":0,"latestPrice":0.365,"committee":-0.917498,"eps":-0.042199,"divideRate":0,"volume":2885030,"delay":0,"ttmEps":-0.042199,"open":0.38,"prevYearClose":0.415,"prevWeekClose":0.395,"prevMonthClose":0.395,"prevQuarterClose":0.415,"fiveDayClose":0.395,"twentyDayClose":0.445,"sixtyDayClose":0.255,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1132253135","title":"IMMUTEP LTD發布關於Imp761的積極進展：首個針對自身免疫疾病的Lag-3激動劑抗體的I期研究結果","url":"https://stock-news.laohu8.com/highlight/detail?id=1132253135","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1132253135?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 21:02","pubTimestamp":1766408522,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD发布关于Imp761的积极进展：首个针对自身免疫疾病的Lag-3激动剂抗体的I期研究结果","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BK7508","IMM.AU"],"gpt_icon":0},{"id":"1173503970","title":"Immutep與Dr. Reddy's達成戰略合作 推廣創新腫瘤藥物Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1173503970","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173503970?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 21:18","pubTimestamp":1765199884,"startTime":"0","endTime":"0","summary":"12月8日 - Immutep Ltd宣布，Immutep与Dr. Reddy’s达成了战略合作协议，共同推广一种创新的肿瘤药物Eftilagimod Alfa。根据协议，Immutep将获得2,000万美元的预付款，以及最高可达3.495亿美元的额外资金。此外，Dr. Reddy's将获得在北美、欧洲、日本及大中华区以外所有国家对Eftilagimod Alfa的独家权利。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","IMM.AU","BK7067"],"gpt_icon":0},{"id":"1138437616","title":"IMMUTEP LTD - DR. Reddy's 獲得所有北美、歐洲、日本及大中華區外國家的Eftilagimod Alfa獨家權利","url":"https://stock-news.laohu8.com/highlight/detail?id=1138437616","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138437616?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 21:09","pubTimestamp":1765199347,"startTime":"0","endTime":"0","summary":"IMMUTEP LTD - DR. Reddy's 获得所有北美、欧洲、日本及大中华区外国家的Eftilagimod Alfa独家权利","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"gpt_icon":0},{"id":"1156951078","title":"IMMUTEP與DR. Reddy’s達成戰略合作，共同推廣創新腫瘤藥物Eftilagimod Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=1156951078","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156951078?lang=zh_tw&edition=fundamental","pubTime":"2025-12-08 21:05","pubTimestamp":1765199131,"startTime":"0","endTime":"0","summary":"IMMUTEP与DR. Reddy’s达成战略合作，共同推广创新肿瘤药物Eftilagimod Alfa。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7508","BK7067","IMM.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":9,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IMM.AU\",params:#limit:6,delay:true,,,undefined,":[{"market":"AU","name":"醫藥生物股","bkCode":"BK7508","id":"package_au_concept_yyswg","changeRate":-0.008451}]}}